Boston Scientific stent infringes Medinol patent.On June 24, 2003 the District Court in Dusseldorf (Patent Chamber) Germany, decided in favor of Medinol (Tel Aviv Tel Aviv (tĕl əvēv`), city (1994 pop. 355,200), W central Israel, on the Mediterranean Sea. Oficially named Tel Aviv–Jaffa, it is Israel's commercial, financial, communications, and cultural center and the core of its largest , Israel) regarding Medinol's infringement law suits against Boston Scientific The Boston Scientific Corporation (NYSE: BSX) (abbreviated BSC), is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, and its director, Mr. Michel Darnaud. Following these decisions, Boston Scientific's "Express" stent stent (stent) 1. a device or mold of a suitable material, used to hold a skin graft in place. 2. a slender rodlike or threadlike device used to provide support for tubular structures that are being anastomosed, or is infringing Medinol's patent EP 762 856 and utility model 295 21 206. The court has examined the Express stent, which Boston Scientific has announced to be in use also in its "Express2" and "Taxus" stents, and found it to be making use of the protected technology of Medinol. Accordingly, Boston Scientific will have to pull all the Express stents from the German market even if Boston Scientific exercises its right to appeal the decision because Medinol intends to secure a deposit to enforce its patent and utility model rights. In addition, the court decided that Medinol is entitled to damages from Boston Scientific. For the purpose of determining the amount of damages, the court ordered Boston Scientific to open its books and records to Medinol. The amount of damages to which Medinol is entitled to receive from Boston Scientific will be determined at a later date. Boston Scientific can appeal this judgment also insofar in·so·far adv. To such an extent. Adv. 1. insofar - to the degree or extent that; "insofar as it can be ascertained, the horse lung is comparable to that of man"; "so far as it is reasonably practical he should practice . The injunction granted by the court against Boston Scientific can be enforced as soon as the decision has been served to Boston Scientific. The Patent Court in Dusseldorf is considered the leading patent court in Europe, since it handles the highest number of patent cases throughout Europe. The legal struggle between Medinol and Boston Scientific started with the filing by Medinol of its major action against Boston Scientific in the Federal Court in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of . Medinol argued in its Claim that Boston Scientific acted systematically over several years with the intent to ruin Medinol, misappropriate mis·ap·pro·pri·ate tr.v. mis·ap·pro·pri·at·ed, mis·ap·pro·pri·at·ing, mis·ap·pro·pri·ates 1. a. To appropriate wrongly: misappropriating the theories of social science. its valuable intellectual property and its highly guarded trade secrets and erected behind Medinol's back a secret plant in Ireland for the production of Medinol's NIR NIR Near Infrared NIR National Inventory Report NIR National Identity Register (UK) NIR Near-Infrared Reflectance NIR Non-Ionizing Radiation NIR Net International Reserves NIR National Internet Registry NIR Northern Ireland Railways stents. The stent is a flexible medical device designed to support the walls of arteries that have been cleaned of fatty deposits via angioplasty angioplasty (ăn`jēōplăs'tē), any surgical repair of a blood vessel, especially balloon angioplasty or percutaneous transluminal coronary angioplasty, a treatment of coronary artery disease. . The global stent market is valued at approximately $2.6 billion. Medinol is a global leader in the field of stents and stenting systems with a vast and most significant portfolio of intellectual property. Medinol has developed a unique approach to the design and manufacture of an extensive product pipeline. Its new generation stents reflect the company's uncompromising commitment to continuous innovation, unique product design and top quality products. Medinol, Ltd. +1-212-601-8316 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion